Clinical trials: Allergic Rhinitis and/or Rhinoconjunctivitis +- Asthma
Allergic Rhinitis, Allergic Asthma
Clinical Trial to Evaluate the Efficacy and Safety of Polymerized, Mannan-Conjugated Dermatophagoides Allergen Extract
Prospective, randomised, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of polymerized and mannan conjugated allergen extract of Dermatophagoides for the treatment of allergic…
- Conditions
- Allergic Rhinitis, Allergic Asthma, Allergic Rhinoconjunctivitis, Allergy to House Dust Mite
- Trial name
- MM09-SLIM (NCT05641272)
- Testing
- 3,000 MM09, 9,000 MM09
- Where
- Argentina
- Volunteers
- 90 people
- Sponsor
- Inmunotek S.L.
Allergy, Rhinitis
Safety Clinical Trial With Depigopid 50% Grasses/50% Olea Europaea(2000DPP/ml) or Depigoid 50% Grasses/50% Parietaria Judaica(2000DPP/ml).
The primary objective of this study is to evaluate the safety and tolerance of a rush build up administration of Depigoid forte pollen and the first maintenance dose administered 4 weeks later.
- Conditions
- Allergy, Rhinitis, Rhinoconjunctivitis, Seasonal Asthma
- Trial name
- NCT01734265
- Testing
- Depigoid 50% Grasses/50% Olea europaea (2000DPP/ml), Depigoid 50% Grasses/50% Parietaria judaica (2000DPP/ml)
- Where
- 4 sites in Spain
- Volunteers
- 63 people
- Sponsor
- Laboratorios Leti, S.L.
Rhinitis Allergic, Conjunctivitis
A Study of SCH 697243 in Participants With Grass Pollen Allergy Symptoms, With or Without Asthma (P08067)
This is a study to evaluate the efficacy and safety of grass sublingual tablet (SCH 697243) versus placebo in the treatment of grass pollen-induced allergic hayfever symptoms.
- Trial name
- NCT01385371
- Testing
- Grass (Phleum pratense) pollen allergen extract
- Volunteers
- 1,501 people
- Sponsor
- ALK-Abelló A/S
Rhinitis, Rhinoconjunctivitis
Efficacy and Safety of SLIT in Patients With Rhinitis/RC With/Without Mild-moderate Asthma, Due to Dpt and/or Df
The goal of this clinical trial is to learn if MM09 works to treat patients allergic to house mites, displaying rhinitis/rhinoconjunctivitis with or without mild to moderate asthma. It will also learn about the safety of MM09.
- Trial name
- Oraltek-58 (NCT07348302)
- Testing
- Allergen Immunotherapy Extract
- Where
- 19 sites in Argentina, China and 2 more
- Volunteers
- 736 people
- Sponsor
- Inmunotek S.L.
Rhinitis, Allergic, Conjunctivitis
Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05234)
This study will evaluate the efficacy and safety of ragweed sublingual tablet (SCH 39641/MK-3641/Amb a 1-U) compared with placebo in participants with ragweed-induced rhinoconjunctivitis over a one-year period.
- Trial name
- NCT00770315
- Testing
- Ambrosia artemisiifolia allergen extract (Amb a 1-U)
- Volunteers
- 784 people
- Sponsor
- ALK-Abelló A/S